Heidelberg University

Running trials

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· Source

• Recruiting

  Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

  NCT07789574· Phase 2· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Source

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· Phase 3· Source

• Not yet recruiting

  A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

  NCT07474649· Phase 3· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Source

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Source

• Recruiting

  Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

  NCT07260175· Phase 2· Source

• Recruiting

  Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

  NCT05293080· Phase 3· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)

  2024-516790-78-00· Phase 2· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Source

• Recruiting

  AZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients

  2024-517237-40-00· Phase 1/2· Source

• Recruiting

  Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

  NCT06717958· Phase 2· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Source

• Recruiting

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· Phase 2· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Recruiting

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· Phase 3· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

  NCT06525220· Phase 3· Source

• Not yet recruiting

  Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

  NCT03865277· Phase 2· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Source

• Active, not recruiting

  Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

  NCT05871021· Phase 2· Source

• Recruiting

  Cohort Study on Plant-based Diets (COPLANT Study)

  NCT06323538· Source

• Recruiting

  Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

  NCT05904106· Phase 2· Source

• Recruiting

  Predicting Esophageal Cancer Borders Using PET-Imaging

  NCT06408116· Phase 2· Source

• Recruiting

  Exploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease

  NCT06580977· Source

• Terminated

  Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT06058156· Phase 2· Source

• Recruiting

  Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

  NCT06061094· Phase 2· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Bladder cancer4 recruiting
• Crohn's disease4 recruiting
• Acute myeloid leukemia3 recruiting
• Coronary artery disease3 recruiting
• Gastric and esophageal cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Childhood cancers2 recruiting
• Chronic kidney disease2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obesity2 recruiting
• Parkinson disease2 recruiting
• Stroke2 recruiting
• Ulcerative colitis2 recruiting
• Atrial fibrillation1 recruiting
• Cystic fibrosis1 recruiting
• Diabetic eye disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Source

• Completed

  Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib

  2024-516073-74-00· Phase 4· Source

• Completed

  With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia

  2024-518971-76-00· Phase 2· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· Source

• Completed

  Validate: Trustworthy AI to Improve Acute Stroke Outcomes

  NCT05622539· Source

• Completed

  Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

  NCT06430671· Phase 1· Source

• Active, not recruiting

  Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

  NCT05182385· Phase 1/2· Source

• Completed

  Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

  NCT04221529· Phase 2· Source

• Terminated

  Spironolactone in the Treatment of Heart Failure

  NCT04727073· Phase 3· Source

• Completed

  Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

  NCT03341520· Phase 2· Source

• Terminated

  A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

  NCT02088060· Phase 2· Source

Trial sites

• Department of General Psychiatry, Heidelberg University1 trial
• Department of General, Visceral and Transplantation Surgery, University of Heidelberg1 trial
• Department of Medicine I (Nephrology), University of Heidelberg1 trial
• Department of Radiation Oncology Heidelberg University Medical School1 trial
• Department of Radiotherapy, University of Heidelberg1 trial
• Heidelberg University5 trials
• Universität Heidelberg6 trials
• University Heidelberg1 trial
• University of Heidelberg5 trials
• Heidelberg University55 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure116 works · 2 trials
• Lung cancer107 works · 6 trials
• Obesity105 works · 2 trials
• Melanoma88 works · 3 trials
• Colorectal cancer85 works · 4 trials
• Schizophrenia69 works · 1 trials
• Glioblastoma68 works · 3 trials
• Sarcoma65 works · 0 trials
• Prostate cancer63 works · 2 trials
• Chronic kidney disease53 works · 3 trials
• Depression48 works · 0 trials
• Pancreatic cancer41 works · 1 trials
• Coronary artery disease40 works · 3 trials
• Ovarian cancer39 works · 2 trials
• Multiple sclerosis37 works · 2 trials
• Acute myeloid leukemia35 works · 4 trials
• COPD34 works · 0 trials
• Multiple myeloma28 works · 0 trials
• Bipolar disorder27 works · 0 trials
• Head and neck cancer25 works · 3 trials
• Amyloidosis24 works · 0 trials
• Macular degeneration21 works · 0 trials
• Cystic fibrosis16 works · 1 trials
• Hypertrophic cardiomyopathy12 works · 0 trials
• Pulmonary arterial hypertension12 works · 0 trials
• Chronic myeloid leukaemia11 works · 4 trials
• Childhood cancers11 works · 2 trials
• Myeloproliferative neoplasms9 works · 2 trials
• Neuromyelitis optica (NMOSD)6 works · 0 trials
• Polycystic kidney disease3 works · 0 trials